Therapy Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

Therapy Name Luveltamab Tazevibulin
Synonyms
Therapy Description

Luveltamab tazevibulin is an antibody-drug conjugate (ADC) that consists of an anti-FolRa human IgG1 antibody linked to the anti-tubulin agent 3-aminophenyl hemiasterlin (SC209), which potentially inhibits growth of FolRa-expressing tumors (PMID: 36459691).

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
Luveltamab Tazevibulin STRO002|STRO 002|STRO002|luvelta FOLR1-targeted Therapy 20 Luveltamab tazevibulin is an antibody-drug conjugate (ADC) that consists of an anti-FolRa human IgG1 antibody linked to the anti-tubulin agent 3-aminophenyl hemiasterlin (SC209), which potentially inhibits growth of FolRa-expressing tumors (PMID: 36459691).

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT05870748 Phase II Luveltamab Tazevibulin Gemcitabine + Paclitaxel + Pegylated liposomal doxorubicin + Topotecan Luveltamab Tazevibulin + Pegfilgrastim REFRaME-O1: A Study to Investigate the Efficacy and Safety of Luveltamab Tazevibulin Versus Investigator's Choice (IC) Chemotherapy in Women With Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing FOLR1 Recruiting USA | CAN | AUS 3
NCT03748186 Phase I Luveltamab Tazevibulin Study of STRO-002, an Anti-Folate Receptor Alpha (FolR?) Antibody Drug Conjugate in Ovarian & Endometrial Cancers Active, not recruiting USA | ESP 0


Additional content available in CKB BOOST